Kartilium is effective in acute and chronic diseases of the joints: arthritis and osteoarthritis based on synovial cartilage damage with secondary changes of the articular surfaces. These diseases are the most common among all the pathologies of the locomotor system and a major cause of disability.

Kartilium has a unique composition of natural substances that can affect the process of inflammation and the condition of the articular cartilage. As part of this composition is standardized root extract of African plants Devil claws (Harpagophytum procumbens), manufactured by Naturex (France), as well as methylsulfonylmethane, manufactured by Eusa (France) – an organic compound which plays an important role in the repair of damaged tissues of the joints.

Due to anti-inflammatory and analgesic properties, root extract is widely used in traditional medicine of peoples in South Africa for gout and rheumatism treatment. In Europe and North America is used primarily to reduce the symptoms of arthritis.

Clinical response of Devil’s claw root extract in inflammatory and degenerative diseases of the joints caused by the action of biologically active substances, the main one is Harpagoside. Specially developed technology allows obtaining the Harpagoside extract at a concentration not less than 20% and respectively advancing tenfold it single dose, as compared to other Devil’s claw root extract. It has been proved that such dose of Harpagoside causes the therapeutic properties of the extract.

Experimental studies have confirmed the therapeutic effectiveness of a standardized extract, namely, reducing inflammation and pain; restore range of motion, improving the functionality and quality of life. Good Kartilium tolerance and lack of influence over gastrointestinal offer the challenge for a wide application for patients with acute and chronic diseases of the joints.

Significant aging of the population of Ukraine determines the increase in the number of patients with osteoarthritis. Timely diagnosis, targeted treatment and the use of modifying agents (glucosamine and chondroitin) will contribute to the prevention of disability, quality of life, active longevity.